Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The ninth ENBDC Weggis meeting: growth and in-depth characterisation of normal and neoplastic breast cells.

Wiese KE, Amante RJ, Vivanco MD, Bentires-Alj M, Iggo RD.

Breast Cancer Res. 2017 Aug 22;19(1):96. doi: 10.1186/s13058-017-0891-9.

2.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

3.

Cluster Analysis of p53 Binding Site Sequences Reveals Subsets with Different Functions.

Lim JH, Latysheva NS, Iggo RD, Barker D.

Cancer Inform. 2016 Oct 25;15:199-209. eCollection 2016.

4.

Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD.

Breast Cancer Res. 2015 Sep 16;17(1):126. doi: 10.1186/s13058-015-0612-1.

5.

Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD.

Breast Cancer Res. 2014 Dec 20;16(6):504. doi: 10.1186/s13058-014-0504-9. Erratum in: Breast Cancer Res. 2015;17(1):126.

6.

Models incorporating chromatin modification data identify functionally important p53 binding sites.

Lim JH, Iggo RD, Barker D.

Nucleic Acids Res. 2013 Jun;41(11):5582-93. doi: 10.1093/nar/gkt260. Epub 2013 Apr 17.

7.

New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours.

Iggo RD.

Breast Cancer Res. 2011;13(6):318. doi: 10.1186/bcr3036. Epub 2011 Dec 8.

8.

Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2011 Feb;12(2):116. doi: 10.1016/S1470-2045(11)70011-0. No abstract available.

PMID:
21277543
9.

Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping.

Funston GM, Kallioinen SE, de Felipe P, Ryan MD, Iggo RD.

J Gen Virol. 2008 Feb;89(Pt 2):389-96. doi: 10.1099/vir.0.83444-0.

PMID:
18198369
10.

Evidence of frequent recombination among human adenoviruses.

Lukashev AN, Ivanova OE, Eremeeva TP, Iggo RD.

J Gen Virol. 2008 Feb;89(Pt 2):380-8. doi: 10.1099/vir.0.83057-0.

PMID:
18198368
11.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
12.

An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells.

Duss S, André S, Nicoulaz AL, Fiche M, Bonnefoi H, Brisken C, Iggo RD.

Breast Cancer Res. 2007;9(3):R38.

13.
14.

RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.

Homicsko K, Lukashev A, Iggo RD.

Cancer Res. 2005 Aug 1;65(15):6882-90.

15.

Determinants of interferon-stimulated gene induction by RNAi vectors.

Pebernard S, Iggo RD.

Differentiation. 2004 Mar;72(2-3):103-11.

PMID:
15066190
16.

Promoter-specific p53-dependent histone acetylation following DNA damage.

Kaeser MD, Iggo RD.

Oncogene. 2004 May 13;23(22):4007-13.

PMID:
15007388
17.

Regulation of p53 stability and function in HCT116 colon cancer cells.

Kaeser MD, Pebernard S, Iggo RD.

J Biol Chem. 2004 Feb 27;279(9):7598-605. Epub 2003 Dec 9.

18.

Replicating parvoviruses that target colon cancer cells.

Malerba M, Daeffler L, Rommelaere J, Iggo RD.

J Virol. 2003 Jun;77(12):6683-91.

19.
20.

Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants.

Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T.

Carcinogenesis. 2001 Mar;22(3):515-7.

PMID:
11238194
21.

Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx.

Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, Iggo RD, Yumoto E.

Int J Cancer. 2000 Mar 20;89(2):187-93.

22.

p53 inactivating mutations in Chinese nasopharyngeal carcinomas.

Lung ML, Hu Y, Cheng Y, Li MF, Tang CM, O SK, Iggo RD.

Cancer Lett. 1998 Nov 13;133(1):89-94.

PMID:
9929165
23.

Monitoring adenoviral p53 transduction efficiency by yeast functional assay.

Tada M, Sakuma S, Iggo RD, Saya H, Sawamura Y, Fujiwara T, Roth JA.

Gene Ther. 1998 Mar;5(3):339-44.

24.

Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay.

Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD.

Acta Neuropathol. 1998 Mar;95(3):291-6. Review.

PMID:
9542595
25.

Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations.

Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y.

Cancer Res. 1998 May 1;58(9):1793-7.

26.

Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide.

Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H.

Mutat Res. 1997 Oct 6;379(2):211-8.

PMID:
9357550
27.

Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.

Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H.

Mol Carcinog. 1997 Mar;18(3):171-6.

PMID:
9115587
28.

Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay.

Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H.

Int J Cancer. 1996 Jul 29;67(3):447-50.

29.

p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts.

Iggo RD, Jamieson DJ, MacNeill SA, Southgate J, McPheat J, Lane DP.

Mol Cell Biol. 1991 Mar;11(3):1326-33.

30.

Nuclear protein p68 is an RNA-dependent ATPase.

Iggo RD, Lane DP.

EMBO J. 1989 Jun;8(6):1827-31.

31.

Using the polymerase chain reaction to modify expression plasmids for epitope mapping.

Mole SE, Iggo RD, Lane DP.

Nucleic Acids Res. 1989 Apr 25;17(8):3319. No abstract available.

Supplemental Content

Support Center